Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC - Episode 2
MARIPOSA OS Data: Shaping Frontline Treatment in EGFR-Mutant NSCLC
Panelists discusses how the MARIPOSA trial demonstrated significant survival improvement with amivantamab plus lazertinib versus osimertinib alone in EGFR-mutant NSCLC, showing a hazard ratio of 0.75 and an expected 12-month survival benefit that could potentially change the natural history of this disease.
Key Overall Survival Findings from MARIPOSA Trial
Main Discussion Topics:
- Summary of recently presented MARIPOSA trial data at the European Lung Cancer Congress 2025
- Discussion of overall survival (OS) benefit with amivantamab plus lazertinib vs osimertinib
- Analysis of the clinical significance of the observed survival benefit
Key Points for Physicians:
- MARIPOSA demonstrated a hazard ratio of 0.75 for OS
- The OS curves between treatment groups continued to widen
Notable Insights:
A 12-month survival benefit is particularly significant in the context of metastatic EGFR-mutant NSCLC, where average survival is approximately 3 years.
Clinical Significance:
The MARIPOSA trial data represent a meaningful advance in treatment outcomes for metastatic EGFR-mutant NSCLC, potentially changing the natural history of the disease through combination therapy.
Related Content:
